136 related articles for article (PubMed ID: 18094399)
1. The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma.
Wang E; Selleri S; Marincola FM
Clin Cancer Res; 2007 Dec; 13(24):7228-31. PubMed ID: 18094399
[No Abstract] [Full Text] [Related]
2. NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.
Maccalli C; Nonaka D; Piris A; Pende D; Rivoltini L; Castelli C; Parmiani G
Clin Cancer Res; 2007 Dec; 13(24):7459-68. PubMed ID: 18094430
[TBL] [Abstract][Full Text] [Related]
3. Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer.
Katou F; Ohtani H; Watanabe Y; Nakayama T; Yoshie O; Hashimoto K
Cancer Res; 2007 Dec; 67(23):11195-201. PubMed ID: 18056444
[TBL] [Abstract][Full Text] [Related]
4. Expression of NK-associated receptors on cytotoxic T cells from melanoma patients: a two-edged sword?
Tarazona R; Casado JG; Soto R; DelaRosa O; Peralbo E; Rioja L; Peña J; Solana R
Cancer Immunol Immunother; 2004 Oct; 53(10):911-24. PubMed ID: 15127235
[TBL] [Abstract][Full Text] [Related]
5. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.
Groh V; Smythe K; Dai Z; Spies T
Nat Immunol; 2006 Jul; 7(7):755-62. PubMed ID: 16732291
[TBL] [Abstract][Full Text] [Related]
6. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
Maccalli C; Scaramuzza S; Parmiani G
Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424
[TBL] [Abstract][Full Text] [Related]
7. NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes.
Upshaw JL; Leibson PJ
Semin Immunol; 2006 Jun; 18(3):167-75. PubMed ID: 16723257
[TBL] [Abstract][Full Text] [Related]
8. NKG2D ligands in tumor immunity.
Nausch N; Cerwenka A
Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
[TBL] [Abstract][Full Text] [Related]
9. NK cells and cancer immunosurveillance.
Waldhauer I; Steinle A
Oncogene; 2008 Oct; 27(45):5932-43. PubMed ID: 18836474
[TBL] [Abstract][Full Text] [Related]
10. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system.
Zwirner NW; Fuertes MB; Girart MV; Domaica CI; Rossi LE
Cytokine Growth Factor Rev; 2007; 18(1-2):159-70. PubMed ID: 17324607
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands.
Solana R; Casado JG; Delgado E; DelaRosa O; Marín J; Durán E; Pawelec G; Tarazona R
Cancer Immunol Immunother; 2007 Jan; 56(1):101-9. PubMed ID: 16485126
[TBL] [Abstract][Full Text] [Related]
12. The role of the NKG2D receptor for tumor immunity.
Coudert JD; Held W
Semin Cancer Biol; 2006 Oct; 16(5):333-43. PubMed ID: 16914326
[TBL] [Abstract][Full Text] [Related]
13. T-cell type lymphoproliferative disease of granular lymphocytes (LDGL) is equipped with a phenotypic pattern typical of effector cytotoxic cells.
Baesso I; Pavan L; Boscaro E; Miorin M; Facco M; Trentin L; Agostini C; Zambello R; Semenzato G
Leuk Res; 2007 Mar; 31(3):371-7. PubMed ID: 16982092
[TBL] [Abstract][Full Text] [Related]
14. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
[TBL] [Abstract][Full Text] [Related]
15. The NKG2D receptor: sensing stressed cells.
López-Larrea C; Suárez-Alvarez B; López-Soto A; López-Vázquez A; Gonzalez S
Trends Mol Med; 2008 Apr; 14(4):179-89. PubMed ID: 18353724
[TBL] [Abstract][Full Text] [Related]
16. NKG2D ligands: key targets of the immune response.
González S; López-Soto A; Suarez-Alvarez B; López-Vázquez A; López-Larrea C
Trends Immunol; 2008 Aug; 29(8):397-403. PubMed ID: 18602338
[TBL] [Abstract][Full Text] [Related]
17. Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL.
Benlalam H; Jalil A; Hasmim M; Pang B; Tamouza R; Mitterrand M; Godet Y; Lamerant N; Robert C; Avril MF; Neefjes J; Tursz T; Mami-Chouaib F; Kieda C; Chouaib S
J Immunol; 2009 Mar; 182(5):2654-64. PubMed ID: 19234159
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
19. The DNA damage response arouses the immune system.
Gasser S; Raulet DH
Cancer Res; 2006 Apr; 66(8):3959-62. PubMed ID: 16618710
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells.
Konjević G; Mirjacić Martinović K; Jurisić V; Babović N; Spuzić I
Biomarkers; 2009 Jun; 14(4):258-70. PubMed ID: 19489688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
